First Results From a Randomized Phase 2 Study of Cabazitaxel vs an Androgen Receptor-Targeted Agent in Patients With Poor-Prognosis Castration-Resistant Prostate Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [21] The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer
    Taniguchi, Hisanori
    Ikeda, Junichi
    Masuo, Yuki
    Kinoshita, Hidefumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [22] Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
    Omlin, Aurelius
    Cathomas, Richard
    von Amsberg, Gunhild
    Reuter, Christoph
    Feyerabend, Susan
    Loidl, Wolfgang
    Boegemann, Martin
    Lorch, Anja
    Heidenreich, Axel
    Tsaur, Igor
    Larcher-Senn, Julian
    Buck, Stefan A. J.
    Mathijssen, Ron H. J.
    Jaehde, Ulrich
    Gillessen, Silke
    Joerger, Markus
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1887 - 1893
  • [23] Sarcopenia and the Therapeutic Effects of Androgen Receptor-axis-targeted Therapies in Patients With Castration-resistant Prostate Cancer
    Hiroshige, Tasuku
    Ogasawara, Naoyuki
    Kumagae, Hisaji
    Ueda, Kosuke
    Chikui, Katsuaki
    Uemura, Kei-Ichiro
    Nishihara, Kiyoaki
    Nakiri, Makoto
    Matsuo, Mitsunori
    Suekane, Shigetaka
    Igawa, Tsukasa
    IN VIVO, 2023, 37 (03): : 1266 - 1274
  • [24] Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy
    Chakrani, Zakaria
    Mellgard, George
    Saffran, Nathaniel
    McCroskery, Stephen
    Taylor, Nicole
    Patel, Mann
    Liaw, Bobby
    Galsky, Matthew
    Oh, William K.
    Tsao, Che-Kai
    Patel, Vaibhav G.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (06): : 271 - 278
  • [25] Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
    Fred Saad
    Kim N. Chi
    Neal D. Shore
    Julie N. Graff
    Edwin M. Posadas
    Jean-Baptiste Lattouf
    Byron M. Espina
    Eugene Zhu
    Alex Yu
    Anasuya Hazra
    Marc De Meulder
    Rao N. V. S. Mamidi
    Branislav Bradic
    Peter Francis
    Vinny Hayreh
    Arash Rezazadeh Kalebasty
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 25 - 37
  • [26] Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
    Saad, Fred
    Chi, Kim N.
    Shore, Neal D.
    Graff, Julie N.
    Posadas, Edwin M.
    Lattouf, Jean-Baptiste
    Espina, Byron M.
    Zhu, Eugene
    Yu, Alex
    Hazra, Anasuya
    De Meulder, Marc
    Mamidi, Rao N. V. S.
    Bradic, Branislav
    Francis, Peter
    Hayreh, Vinny
    Rezazadeh Kalebasty, Arash
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (01) : 25 - 37
  • [27] Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)
    Morgans, A. K.
    Hutson, T. E.
    Guan, A. K.
    Garcia, D.
    Zhou, A.
    Drea, E. J.
    Vogelzang, N. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S636 - S637
  • [28] A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
    Rathkopf, Dana E.
    Picus, Joel
    Hussain, Arif
    Ellard, Susan
    Chi, Kim Nguyen
    Nydam, Thomas
    Allen-Freda, Erin
    Mishra, Kaushal Kishor
    Porro, Maria Grazia
    Scher, Howard I.
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 537 - 544
  • [29] A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
    Dana E. Rathkopf
    Joel Picus
    Arif Hussain
    Susan Ellard
    Kim Nguyen Chi
    Thomas Nydam
    Erin Allen-Freda
    Kaushal Kishor Mishra
    Maria Grazia Porro
    Howard I. Scher
    George Wilding
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 537 - 544
  • [30] Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?
    Geynisman, Daniel M.
    Plimack, Elizabeth R.
    Zibelman, Matthew
    EUROPEAN UROLOGY, 2016, 70 (06) : 971 - 973
12345